BioSpectrum India on MSN
Fatty liver disease management: antifibrotic treatment, disease staging and transplant eligibility
Fatty liver disease is common, but it needs timely attention when inflammation and scarring begin. Non-Alcoholic ...
Scientists have discovered that a potential new drug can reverse severe fatty liver disease in animal models by restoring gut ...
"Research has shown that being inactive is one of the strongest predictors of disease progression and early death. That may ...
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
YAQ001 associated with favorable shifts in gut microbial species and lower abundance of virulence and antibiotic resistance genesTrends toward ...
The mechanisms that cause the world's most common chronic liver disease—metabolic dysfunction-associated steatotic liver ...
A new study led by investigators from Mass General Brigham found routine liver cancer screening to be cost-effective and life ...
For the first time, many people living with chronic hepatitis B may have a functional cure at hand. The US Food and Drug ...
Some adults with chronic hepatitis B may now have a path to something today's treatments rarely deliver—stopping all ...
A rare inherited change in a single gene may directly cause fatty liver disease in some people, even when they lack familiar ...
FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.
Mens Fitness on MSN
FDA Approves Hibsago, a Hepatitis B Treatment That Could Let Some Patients Stop Therapy
FDA-approved Hibsago could help some adults with chronic hepatitis B stop antiviral therapy. Learn who qualifies, what trials found, and the key risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results